# Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

> **NCT00291057** · PHASE2 · TERMINATED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Lice Infestations

## Interventions

- **DRUG:** MALG

## Key facts

- **NCT ID:** NCT00291057
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2006-10
- **Final completion:** 2006-12
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2013-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291057, "Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00291057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*